Association of toll-interacting protein gene polymorphisms with atopic dermatitis

Tobias T Schimming¹, Qumar Parwez², Elisabeth Petrasch-Parwez³, Michael Nothnagel⁴, Joerg T Epplen¹ and Sabine Hoffjan*¹

Address: ¹Department of Human Genetics, Ruhr-University Bochum, Bochum, Germany, ²Private medical practice, Gladbeck, Germany, ³Department of Neuroanatomy and Molecular Brain Research, Ruhr-University Bochum, Bochum, Germany and ⁴Institute for Medical Informatics and Statistics (IMIS), University of Kiel, Kiel, Germany

Email: Tobias T Schimming - Schimming@gmx.net; Qumar Parwez - QumarParwez@t-online.de; Elisabeth Petrasch-Parwez - elisabeth.petrasch-parwez@rub.de; Michael Nothnagel - nothnagel@medinfo.uni-kiel.de; Joerg T Epplen - joerg.t.epplen@rub.de; Sabine Hoffjan* - sabine.hoffjan@rub.de

* Corresponding author

Abstract

Background: Atopic dermatitis (AD) is a common inflammatory skin disorder, affecting up to 15% of children in industrialized countries. Toll-interacting protein (TOLLIP) is an inhibitory adaptor protein within the toll-like receptor (TLR) pathway, a part of the innate immune system that recognizes structurally conserved molecular patterns of microbial pathogens, leading to an inflammatory immune response.

Methods: In order to detect a possible role of TOLLIP variation in the pathogenesis of AD, we screened the entire coding sequence of the TOLLIP gene by SSCP in 50 AD patients. We identified an amino acid exchange in exon 6 (Ala222Ser) and a synonymous variation in exon 4 (Pro139Pro). Subsequently, these two variations and four additional non-coding polymorphisms (-526 C/G, two polymorphisms in intron 1 and one in the 3'UTR) were genotyped in 317 AD patients and 224 healthy controls.

Results: The -526G allele showed borderline association with AD in our cohort (p = 0.012; significance level after correction for multiple testing 0.0102). Haplotype analysis did not yield additional information. Evaluation of mRNA expression by quantitative real-time polymerase chain reaction in six probands with the CC and six with the GG genotype at the -526 C/G locus did not reveal significant differences between genotypes.

Conclusion: Variation in the TOLLIP gene may play a role in the pathogenesis of AD. Yet, replication studies in other cohorts and populations are warranted to confirm these association results.

Background

Atopic dermatitis (AD) is an inflammatory skin disease characterized by pruritus and chronic or relapsing eczematous lesions that commonly presents during early infancy and affects up to 16% of children [1]. AD has a multifactorial background, with genetic predisposition...
and environmental factors contributing to disease susceptibility [2]. In industrialized countries AD prevalence has increased during the past decades [3], and it has been postulated in the so-called 'hygiene hypothesis' that the lack of contact to microbial products in early infancy might at least in part be responsible for this increase [4]. There is evidence from prospective studies to support an inverse relationship between AD and exposure to endotoxin, a cell membrane component of gram negative bacteria, early day-care attendance and animal exposure [5].

Recognition of microbial products such as endotoxin is mediated by the innate immune system. Toll-like receptors (TLRs) are a family of evolutionarily conserved receptors that recognize pathogen-associated molecular patterns (PAMPs), leading to an inflammatory response by induction of interleukins and other pro-inflammatory proteins [6]. Polymorphisms in TLR genes have been implicated in various diseases [7] including AD [8]. Yet, the effect of genetic variation in TLR downstream signalling pathways has not been sufficiently studied yet. Toll-interacting protein (TOLLIP) is an adaptor protein that acts as an inhibitory factor in the TLR-signalling cascade [9-11]. It functions downstream of MyD88 and TIR domain containing adaptor protein (TIRAP) through inhibition of Interleukin-1 receptor associated kinase 1 (IRAK1) [10] and controls the magnitude of inflammatory cytokine production in response to endotoxin [12]. The TOLLIP gene is located on chromosome 11p15 and comprises 6 exons encoding a 274 amino acid transcript. The 11p15 region has so far not been reported as a linkage region for AD in the four published genome screens [13]. Yet, association studies are generally supposed to have a greater power to detect common alleles with modest effects on disease susceptibility than linkage studies [14]. Furthermore, dysregulated inhibition in the TLR-signalling cascade may cause a pathologically increased or reduced inflammatory response, and variations in the ST2 gene, encoding another inhibitory protein in the TLR pathway, were recently found to be associated with AD [25]. Therefore, we considered the TOLLIP gene an interesting candidate gene for AD.

We screened the entire coding region of the TOLLIP gene by single strand conformation polymorphism (SSCP) analysis in 50 AD patients in order to identify coding variation that might play a role for AD pathogenesis. Subsequently, the identified polymorphisms were genotyped in 317 AD patients and 224 healthy controls to evaluate a possible association with AD. In order to provide a more complete and valuable assessment of variation in the TOLLIP gene, we additionally typed four non coding polymorphisms (located in the promoter and intronic regions as well as in the 3'UTR) that were chosen from the HapMap database [15].

Methods

Subjects

317 unrelated patients with atopic dermatitis were recruited by a consultant specialist for AD (Q.P., Gladbeck, Germany), including 193 children and 124 adults. The AD diagnosis was based on the presence of clinical features, including pruritus, eczema with age-dependent differences in location, xerosis and chronic or relapsing dermatitis. In addition, all investigated AD patients had a positive family history for atopic diseases. 224 control samples from adults without known allergies, asthma or AD were collected in the same private practice as the AD patients. We specifically chose to use non-allergic adults as controls because for diseases as frequent as AD, the risk remains very high for asymptomatic children to develop an allergic disease during childhood or even adulthood [16,17]. The control subjects underwent clinical examination in order to exclude symptoms of AD, asthma or allergic rhinitis, had no self-reported allergies or allergic symptoms and no first degree relatives with known allergic diseases. All patient and control subjects were Caucasians of German origin. Informed consent was obtained from all subjects. The study was approved by the Ethics Committee of the Ruhr-University, and the Declaration of Helsinki protocols were followed.

Preparation of DNA and RNA

DNA was extracted from EDTA anti-coagulated peripheral blood by using a standard salting-out method [18]. Total RNA samples were extracted from EBV-transformed lymphoblastoid cell lines using TriFast reagent (Peqlab) according to the manufacturer's instructions up to the point of phase separation. Afterwards, the aqueous phase was transferred to an RNEasy column (Qiagen, Hilden, Germany) and processed according to the manufacturer's protocol. OD260 and OD280 were determined and the RNA was stored at -70°C until use.

Single strand conformation polymorphism analysis

The entire coding region of the TOLLIP gene was screened for polymorphisms by polymerase chain reaction (PCR) with consecutive single strand conformation polymorphism (SSCP) analysis. PCR reactions were performed in a total volume of 10 μl containing 50 ng DNA, 200 mmol of each dNTP, 0.4 U Taq polymerase (Genecraft, Münster, Germany), GC-Buffer (Genecraft, Münster, Germany), and 0.1 μl [32P] α-CTP (10 mCi/ml). Thermal cycling was conducted in a thermal cycler (Biometra, Göttingen, Germany). After a denaturation step at 95°C for 5 minutes followed by two initial cycles at 6°C and 3°C above the annealing temperature, 28 cycles with 95°C (30 sec), annealing temperature (30 sec) and 72°C (30 sec) were run. Further details for primers and conditions are given in table 1. For SSCP analysis, 3 μl of the PCR product was mixed with 7 μl of SSCP loading buffer (95% formamide,
20 mM EDTA, 0.05% xylene cyanol and 0.05% bromophenol blue), denatured for 5 minutes at 95 °C and thereafter directly cooled on ice. Then 2.5 μl were applied on 6% polyacrylamide gels (38% acrylamide, 2% bisacrylamide) containing 1× TBE buffer (890 mM Tris-borate, 20 mM EDTA, pH 8.3) and 10% glycerine in a SQ3 apparatus (Hoefer, Freiburg, Germany) at 55 W for about 210 minutes. The room temperature was constantly held at 4 °C during SSCP analyses.

**DNA sequencing**

DNA samples showing mobility shifts on SSCP gels were directly sequenced on an automated capillary DNA sequencer (MegaBace 1000, Amersham Biosciences), using the BigDye cycle sequencing kit (Applied Biosystems, Darmstadt, Germany) as described in the manufacturer's instructions.

**Genotyping**

All six polymorphisms in the **TOLLIP** gene were genotyped by restriction enzyme digestion (see Table 1). Patient and control samples were amplified using the same primers and conditions as described above, except for the inclusion of radioactivity. After digestion with the respective enzymes for at least three hours, the fragments were separated on 2% agarose gels in 1× TBE buffer (45 min, 200 V) and visualized by staining with ethidium bromide.

**Measurement of mRNA levels by quantitative real-time PCR**

We carried out real-time PCR on an I-Cycler (Bio Rad Laboratories, Hercules, USA). The quantity of PCR products was determined after each round of amplification using the fluorescent dye SYBR Green I (Qiagen), which binds double-stranded DNA. The primer sequences (F: 5'-AGTACGGAGGCGAGGCAGTG-3'; R: 5'-AGCCGGCAGTCCG-GACAGTC-3') represent parts of two adjacent exons in order to prevent amplification of potential traces of contaminating genomic DNA. PCR reactions were run in triplicates (95 °C for 5 min, 56 °C for 30 sec, 95 °C for 1 min, 55 °C for 30 sec). Fluorescence was recorded at the end of each extension step, and a melting curve was obtained at the end of each run. Quantification of the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase- (GAPDH-) mRNA (primers F: 5’-TGTGTCGCTCGCT-GATCTGA-3'; R: 5’-CCTGCTTCACCACCTTCTTGA-3'; product size 76 bp) was used as a control for data normalization. After the PCR, products were analyzed on agarose gels in order to verify band sizes and purity. Expression was assessed by evaluating threshold cycle (Ct) values. The Ct values were calculated by the system software (iCycler), and the relative amount of expressed RNA was calculated using Livak's method [19].

**Table 1: Primer sequences, PCR conditions and restriction enzymes used for mutation analysis and genotyping of selected polymorphisms in the **TOLLIP** gene.**

| Amplicon | Rs number | Amino acid | Primer | Annealing temperature | MgCl₂ (mmol/l) | Restriction enzyme |
|----------|-----------|------------|--------|-----------------------|----------------|-------------------|
| TOLLIP-526 C/G | 5743854 | - | F: GGGTGACCTTCGGACGCTG | 57°C | 2 | Hind6l |
| TOLLIP exon 1* | - | - | F: GACAACTGTCTCCGTCGCA | 55°C | 2 | - |
| TOLLIP intron1a | 5743867 | - | F: ACTCTCCCAGACCTGACCTAAG | 61°C | 4 | Mbol |
| TOLLIP intron1b | 11042484 | - | F: GACCACGCTTCGTCAGG | 62°C | 2 | Hind6l |
| TOLLIP exon 2* | - | - | F: ACCCTGACTCTGGCCTTC | 58°C | 2 | - |
| TOLLIP exon 3* | - | - | F: GTTGGGACCCCTCCTTCTCTGAC | 66°C | 2 | - |
| TOLLIP exon 4 | 3750920 | Pro139Pro | F: GGGCCCTCTCCTCCTTGGC | 60°C | 3 | MspI |
| TOLLIP exon 5* | - | - | F: GGTCTCTGGTGATCTGTCG | 66°C | 2 | - |
| TOLLIP exon 6 | 5744015 | Ala222Ser | F: TTGCAGGGTTTACCAATAATTGATG | 63°C | 2 | MwoI |
| TOLLIP 3’UTR | 3750919 | - | F: AGGACCTACCTCAACTCAGC | 58°C | 3 | Alw26I |

F = forward primer, R = reverse primer,

*Amplicons were only amplified for SSCP analysis; no coding variation was discovered with this method.*
improves an approach proposed by Nyholt [21], and consequently single-test p-values < 0.0102 were considered to be significant. Deviations from Hardy-Weinberg equilibrium were evaluated using the FINETTI program. The FamHap software [22] was used for haplotype frequency estimation. 95% confidence intervals for the haplotype frequency estimates were constructed using 10,000 bootstrap samples with replacement (non-parametric bootstrap). We performed power analyses with the Genetic Power Calculator program [23]. Potential binding sites for transcription factors at the -526 C/G locus were evaluated using a transcription factor prediction program [24]. For quantitative real-time PCR, the relative amount of expressed RNA was calculated by using Livak's method [19]. Differences between genotypes were assessed by using the REST 2005 beta V1.9.9 software [25].

Results
Screening of the coding region of the TOLLIP gene revealed two exonic polymorphisms: a synonymous variation in exon 4 (Pro139Pro) and an amino acid substitution in exon 6 (Ala222Ser). Four additional SNPs in non-coding regions (-526 C/G, Intron1a, Intron1b, 3’UTR) were chosen from the HapMap database [15]. Evaluation of these polymorphisms in 317 AD patients and 224 controls showed a modest association of the -526 C/G promoter SNP with AD (table 2). The C allele of the -526 G/C promoter polymorphism was significantly more frequent in AD patients than in healthy controls (12.7% vs. 7.7%), uncorrected p-value = 0.012). This polymorphism was in strong linkage disequilibrium (LD) with the Intron1a SNP, and the Pro139Pro variation was in moderate LD with the 3’UTR SNP (r² = 0.64 and 0.20, resp.). Therefore, we felt that Bonferroni correction for independent tests would be overly conservative and applied Li & Ji’s multiplicity correction for SNPs that are in LD with each other and, thus, dependent [20]. This approach yielded a significance level of 0.0102 to keep an overall level of 0.05 in both the cases and the control group. Our finding (p = 0.012), therefore, showed borderline significance, being slightly higher than the significance level. Additionally, the Intron1a G allele was more frequent in AD patients (8.8% vs. 5.6%) while the 222Ser allele showed an increased frequency in healthy controls (5.4% vs. 2.7%). Yet, significance was not evident after correction for multiple testing for both polymorphisms. For the other three variations, no difference in allele or genotype frequencies was found between AD patients and controls. We repeated our analyses within the subgroup of patients with elevated IgE levels and saw the same trend within this subgroup, with the -526G, the Intron1a G allele and the 222Ala allele being more prevalent in cases than in controls (data not shown). Yet, because of the reduction in sample size, the results did not reach statistical significance. All investigated polymorphisms were in Hardy-Weinberg equilibrium in cases and controls. We performed power analyses with the Genetic Power Calculator [23]. Given a multiplicative model with a genotypic relative risk of 2 for heterozygotes and 4 for homozygotes and a D’ of 0.9, we would have 96% power to detect a potential effect. Choosing more conservative parameters, with a genotypic relative risk of 1.5/2.25 and D’ of 0.8, would yield only 48% power. Haplotype analysis did not yield significant results (table 3). We did not find evidence for a pair wise interaction between SNPs within the TOLLIP gene (data not shown).

Because of the observed borderline association of the -526 C/G polymorphism with AD, we searched for potential binding sites for transcription factors at this locus using a transcription factor prediction program [24]. Differential binding of two transcription factors was predicted for the two different alleles at this locus. While the G allele gave a putative binding site for the AP2-γ transcription factor, the C allele showed a putative binding site for E2F. The mRNA expression in B-lymphocyte cultures from six probands with the C/C genotype and six probands with the G/G genotype did not show any differences in expression between the genotypes (figure 1).

Discussion
The innate immune response initiated by TLRs is an important mechanism in defense against pathogenic microorganisms, and variations in TLR genes have been implicated in the pathogenesis of allergic as well as autoimmune diseases [7]. Several studies have pointed out that the innate immune system plays an important role in AD pathogenesis. For example, epidemiological studies showed an inverse relationship between AD and exposure to endotoxin (lipopolysaccharide, LPS), early day-care attendance and animal exposure [5], suggesting that lack of contact to microbial products might increase risk for AD. Further, TLRs were found to be up-regulated in circulating monocytes from AD patients [26]. A polymorphism in the TLR2 gene was associated with a severe AD phenotype [8]. Additionally, variations in the CD14 gene, encoding part of the cell membrane receptor for LPS, as well as in the CARD15 gene, encoding an intracellular LPS receptor, have shown associations with AD [27,28]. Thus, genes in the downstream pathway of TLR signalling also constitute reasonable candidate genes for this frequent skin disease. We demonstrate here first evidence for an association of AD with variation in the TOLLIP gene, encoding a protein with an inhibitory function in the TLR signalling pathway.

Screening of the coding region of the TOLLIP gene by SSCP identified two coding variations: Pro139Pro and Ala222Ser. The rate of detection of nucleotide variants by SSCP varies between 80% and close to 100% under opti-
mized conditions [29]. Thus, it is possible that rare variations might have been missed with this approach. Yet, for multifactorial diseases like AD, common instead of rare variations have been suggested to play a role for pathogenesis [30]. Therefore, we chose to additionally type four frequent SNPs in non-coding regions from the HapMap database. We found a modest association of a promoter polymorphism (-526 C/G) in the TOLLIP gene with AD. Since Bonferroni correction has been controversial for genetic association studies because it might be overly conservative [31], we chose to use a method for multiplicity correction when SNPs in linkage disequilibrium (LD) are

| Polymorphism   | Genotype | Allele | AD     | Controls | p-value |
|----------------|----------|--------|--------|----------|---------|
| -526 C/G       | C/C      | 240 (76.9%) | 181 (84.6%) |
|                | C/G      | 65 (20.8%)  | 33 (15.4%)  |
|                | G/G      | 7 (2.2%)    | 0 (0%)      |
|                | n        | 312        | 214       |
|                |          | 545        | 395       |
|                |          | 79 (12.7%)  | 33 (7.7%)  |
|                |          | 624        | 428       |
| Intron1a       | A/A      | 265 (83.6%) | 199 (88.8%) |
|                | A/G      | 48 (15.1%)  | 25 (11.2%)  |
|                | G/G      | 4 (1.3%)    | 0 (0%)      |
|                | n        | 317        | 224       |
|                |          | 578 (91.2%) | 423 (94.4%) |
|                |          | 56 (8.8%)   | 25 (5.6%)   |
| Intron1b       | A/A      | 2 (0.6%)    | 3 (1.3%)    |
|                | A/G      | 54 (17.3%)  | 39 (17.5%)  |
|                | G/G      | 256 (82.1%) | 181 (81.2%) |
|                | n        | 312        | 223       |
|                |          | 58 (9.3%)   | 45 (10%)    |
|                |          | 566 (90.7%) | 401 (90%)   |
| Pro139Pro      | C/C      | 92 (30.4%)  | 64 (30.0%)  |
|                | C/T      | 147 (48.5%) | 113 (53.1%) |
|                | T/T      | 64 (21.1%)  | 36 (16.9%)  |
|                | n        | 303        | 213       |
|                |          | 331 (54.6%) | 241 (56.6%) |
|                |          | 275 (45.4%) | 185 (43.4%) |
| Ala222Ser      | Ala/Ala  | 293 (94.5%) | 198 (89.6%) |
|                | Ala/Ser  | 17 (5.5%)   | 22 (9.6%)   |
|                | Ser/Ser  | 0 (0%)      | 1 (0.5%)    |
|                | n        | 310        | 221       |
|                |          | 603 (97.3%) | 418 (94.6%) |
|                |          | 17 (2.7%)   | 24 (5.4%)   |
| 3'UTR          | G/G      | 193 (61.5%) | 133 (60.5%) |
|                | A/G      | 105 (33.4%) | 76 (34.6%)  |
|                | A/A      | 16 (5.1%)   | 11 (5.0%)   |
|                | n        | 314        | 220       |
|                |          | 491 (78.2%) | 342 (77.7%) |
|                |          | 137 (21.8%) | 98 (22.3%)  |
|                |          | 628        | 440       |

*According to the method of multiplicity correction for SNPs in LD that was introduced by Li & Ji [20], we considered p-values < 0.0102 as significant.
tested that was introduced by Li & Ji [20]. Our observed p-value of 0.012 for the -526 C/G promoter SNP was borderline significant with respect to Li & Ji’s method (0.0102). We therefore believe that it might represent a true association. Haplotype analysis did not yield additional information.

Interestingly, functional SNPs in the distal promoter of the ST2 gene were recently found to be associated with AD in the Japanese population [32]. Both TOLLIP and ST2 exert inhibitory functions in the TLR cascade [9,33], and for the TOLLIP gene we also saw the most significant although borderline association with the promoter SNP. Therefore, we decided to further explore the role of the -526 C/G variation for AD. Investigation of potential binding sites for transcription factors at the -526 C/G locus using a transcription factor prediction program predicted differential binding of two transcription factors (AP2-γ and E2F) for the two different alleles at this locus. Interestingly, E2F is an important factor in the control of skin pro-

### Table 3: TOLLIP haplotype frequencies in AD patients and controls.

| Haplotype          | Frequency in AD patients (n = 312) | 95%-CI* | Frequency in controls (n = 222) | 95%-CI* |
|--------------------|-----------------------------------|---------|---------------------------------|---------|
| C-A-G-T-G-G        | 0.437                             | 0.396–0.477 | 0.421                           | 0.376–0.466 |
| C-A-G-C-G-A        | 0.202                             | 0.169–0.236 | 0.205                           | 0.169–0.245 |
| C-A-G-C-G-G        | 0.106                             | 0.081–0.133 | 0.138                           | 0.104–0.175 |
| C-A-A-G-C-G-G      | 0.091                             | 0.069–0.114 | 0.090                           | 0.063–0.119 |
| G-G-G-C-G-G        | 0.083                             | 0.061–0.107 | 0.055                           | 0.034–0.076 |
| G-A-G-C-G-G        | 0.031                             | 0.016–0.046 | 0.023                           | 0.009–0.039 |
| C-A-G-C-T-G        | 0.026                             | 0.014–0.039 | 0.041                           | 0.022–0.061 |

*95% confidence interval for the haplotype frequency estimate using 10,000 bootstrap samples with replacement (non-parametric bootstrap).

Figure 1
TOLLIP mRNA expression in six individuals with the genotype GG (ID numbers 1–6) and six individuals with the genotype CC (ID numbers 7–12) at the -526 C/G locus. Total RNA samples were extracted from EBV-transformed lymphoblastoid cell lines and mRNA levels measured by quantitative real-time PCR. For each individual, mRNA expression is shown relative to the mean expression of the six individuals with the opposite genotype. The range of expression changes is less than 2-fold for each individual except ID11. No significant differences in TOLLIP mRNA expression between genotypes were obvious.
liferation [34], and the AP2 family appears to regulate the expression of genes required for the development of ectodermal tissues, including skin [35]. In order to detect a possible direct influence of the TOLLIP -526C/G polymorphism on mRNA expression, we performed quantitative real-time PCR for measurement of mRNA amounts in lymphoid cell cultures from six probands with the C/C and six with the G/G genotype at this locus. Yet, we were unable to find differences in mRNA expression with this method. There are several explanations for this finding. First, a variation that is more distal to the promoter and in LD with the -526 C/G polymorphism or some promoter haplotypes might be the true disease-associated variation. In fact, the recently identified functional SNPs in the ST2 promoter are also located very distal from the transcription start (-26999 and -27639, resp. [32]). Second, measuring mRNA expression via quantitative real-time PCR may not represent the most sensitive method to detect moderate differences in promoter function. Third, expression studies in keratinocytes instead of blood B-lymphocytes would be more informative for a chronic skin disease such AD. Finally, since our association results are somewhat borderline, there may indeed be no functional significance of the analyzed promoter SNP. Yet, functional studies including electro-mobility shift assays (EMSA) are needed to further evaluate the functional relevance of the -526 C/G promoter polymorphism in the TOLLIP gene.

We cannot exclude the possibility that the association result we found for the TOLLIP promoter polymorphism may be caused by another SNP in TOLLIP or a neighbouring gene that is in LD with this variation. For example, the intron 1a SNP that is in LD with the -526C/T polymorphism and the Ala222Ser variation in exon 6 also showed marginal evidence for an association with AD. Further, we are aware of the fact that genetic association studies bear the risk of false-positive results caused by hidden population substructures. Yet, all our patients and controls were of German origin and recruited in North Rhine Westfalia. Even if some of the patient families and controls might originate from neighbouring European countries, a recent study demonstrated that linkage disequilibrium patterns are conserved across European samples for most gene regions [36]. Thus, we consider the risk that our results are caused by hidden population substructures to be marginal, at most. Yet, population stratification could in principle contribute to the borderline significant results we observed in our association study. Finally, the relatively small size of our sample bears the risk of small power, potentially causing false-negative association results. Yet, power analyses indicated that considering a multiplicative model with a genotypic relative risk of 2 for heterozygotes and 4 for homozygotes and a D’ of 0.9, we would have a 96% power to detect a potential effect of a chosen marker. Choosing more conservative parameters, with a genotypic relative risk of 1.5/2.25 and D’ of 0.8, would yield only 48% power. On the other hand, the cohort we present here has been thoroughly recruited by a single physician, so that it constitutes a highly controlled sample with exclusion of many potential confounders. In any case, the borderline evidence for association of TOLLIP variation with AD that we present in this study clearly needs to be replicated in additional studies and populations in order to rule out false positive results.

**Conclusion**

We present first evidence for an association of TOLLIP variation with atopic dermatitis. Our results, although borderline, support the concept that genetic variation in the TLR system may play an important role in the pathogenesis of AD. In combination with recently published association findings for the ST2 gene [32], we suggest that dysregulation of inhibition in the TLR pathway might be of special importance. Yet, the exact mechanism by which variation in negative regulators of TLR signalling may influence AD pathogenesis still needs to be explored. Targeting TLRs has already been discussed as a novel therapeutic option for allergic diseases [37,38]. Thus, better understanding of the molecular pathogenesis of AD could eventually lead to new options in prevention and treatment of this frequent skin disease.

**List of abbreviations used**

- AD: atopic dermatitis
- LD: linkage disequilibrium
- PAMP: pathogen-associated molecular pattern
- PCR: polymerase chain reaction
- SNP: single nucleotid polymorphism
- SSCP: single strand conformation polymorphism
- TLR: Toll-like receptor
- TOLLIP: Toll-interacting protein

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors’ contributions**

TS performed the experiments and drafted the manuscript. QP and EPP recruited the patients as well as controls and collected clinical data. MN performed the statistical analyses. JTE participated in the design and coordination of the study. SH was in charge of the design.
and coordination of the study as well as the statistical analyses and finalised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was supported by the "Forschungsforderung der Ruhr-Universität Bochum Medizinische Fakultät" (FoRUM) grants #F377-2003 and #F480-2005. S.H. was supported by a "Lise-Meitner" grant 2006 of the Ministry for Innovation, Science and Technology North-Rhine Westfalia. We thank Daniela Falkenstein and Svenja Krause for technical assistance and the patients for participating in this study.

References

1. Williams H, Robertson C, Stewart A, Ait-Khaled N, Anabwani G, and the German Working Group for Innovative, Science and Technology North-Rhine Westfalia. We acknowledge the support of the German National Genome Research Network and approved the final manuscript.

2. Boguniewicz M, Leung DY: Pathophysiologic mechanisms in atopic dermatitis. Semin Cutan Med Surg 2001, 20(4):217-225.

3. Williams HC: Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000, 25(7):522-529.

4. Borchers AT, Keen CL, Gershwin ME: Hope for the hygiene hypothesis: when does the dirt hit the fan? J Allergy 2005, 103(1 Pt 2):125-138.

5. Kabesch M, Lauener RP: Pathways of Toll-like receptors and the genetics of innate immunity. Curr Opin Clin Immunol 2003, 16(1):3-9.

6. Cook DN, Hollingsworth JW Jr, Schwartz DA: Toll-like receptors and the genetics of innate immunity. Curr Opin Clin Immunol 2003, 16(1):523-529.

7. Ahmadnejad P, Mrabat-Dahi S, Breuer K, Klotsz M, Werfel T, Herz U, Heeg K, Neumaier M, Renz H: The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004, 113(3):565-567.

8. Bulteau LA, Brouns S, Verbeke K, Barbier V, Dirix W, De Pauw R, de Kozak R, de Maeyer L, de Vos W: A new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2000, 2(6):346-351.

9. Zhang G, Ghosh S: Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002, 277(9):7059-7065.

10. Li J, Ji L: Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005, 95(3):221-227.

11. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004, 74(4):765-769.

12. Becker T, Knapp M: Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet Epidemiol 2004, 27(1):21-32.

13. Genetic Power Calculator [http://pngu.mgh.harvard.edu/~purcell/gpc/]

14. TESS: Transcription Element Search System. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=JG]

15. REST: Relative Expression Software Tool. [http://rest-gene-quantification.info/]

16. Nagata N, Oshida T, Yoshida NL, Yuyama N, Sugita Y, Tsujimoto G, Katsunuma T, Akasawa A, Saito H: Analysis of highly expressed genes in monocytes of atopic dermatitis patients. Int Arch Allergy Immunol 2003, 132(2):156-167.

17. De Marco R, Locatelli F, Cerveri I, Bugiani M, Marinoni A, Giammanco G: Incidence and remission of atopic dermatitis: a retrospective study on the natural history of asthma in Italy. J Allergy Clin Immunol 2002, 110(2):228-235.

18. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16(3):1215.

19. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.

20. Li J, Ji L: Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005, 95(3):221-227.

21. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004, 74(4):765-769.

22. Becker T, Knapp M: Maximum-likelihood estimation of haplotype frequencies in nuclear families. Genet Epidemiol 2004, 27(1):21-32.

23. Genetic Power Calculator [http://pngu.mgh.harvard.edu/~purcell/gpc/]

24. TESS: Transcription Element Search System. [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=JG]

25. REST: Relative Expression Software Tool. [http://rest-gene-quantification.info/]

26. Nagata N, Oshida T, Yoshida NL, Yuyama N, Sugita Y, Tsujimoto G, Katsunuma T, Akasawa A, Saito H: Analysis of highly expressed genes in monocytes of atopic dermatitis patients. Int Arch Allergy Immunol 2003, 132(2):156-167.

27. Litonjua AA, Belanger K, Celedon JC, Milton DK, Bracken MB, Kraft P, Triche EW, Sredl DL, Weiss ST, Leaderer BP, Gold DR: Polymorphisms in the S region of the CD14 gene are associated with eczema in young children. J Allergy Clin Immunol 2005, 115(5):1056-1062.

28. Kabesch M, Peters W, Carr D, Leopold W, Weiland SK, von Mutius E: Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J Allergy Clin Immunol 2003, 111(4):813-817.

29. Jackel S, Epplen JT, Kauth M, Mittersch T, Tschentscher F, Epplen C: Polymerase chain reaction-single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes. Electrophoresis 1998, 19(18):3055-3061.

30. Barnes KC: Genetic epidemiology of health disparities in allergy and clinical immunology. J Allergy Clin Immunol 2006, 117(2):243-54; quiz 255-6.

31. Penneyker TV: What's wrong with Bonferroni adjustments. BMJ 1998, 316(7139):1236-1238.

32. Shimizu M, Matsuda A, Yangasakawa K, Hirota T, Akahoshi M, Inomata N, Ebe K, Tanaka K, Sugihara H, Nakashima K, Tamarai M, Takahashi N, Obara K, Enomoto T, Okayama Y, Gao PS, Huang SK, Tominaga S, Ikawa Z, Shirakawa T: Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005, 14(19):2919-2927.

33. Liew FY, Liu H, Xu D: A novel negative regulator for IL-1 receptor and Toll-like receptor 4. Immunol Lett 2005, 96(1):27-31.

34. Ivanova IA, D’Souza SJ, Dagnino L: Signalling In The Epidermis: The E2F Cell Cycle Regulatory Pathway In Epidermal Morphogenesis, Regeneration And Transformation. Int J Biol Sci 2005, 1(2):87-95.

35. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC: Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996, 35(1):262-264.

36. Mueller JC, Lohmusaaar E, Magi R, Remm M, Bettecken T, Lichtner P, Dzenis D, Dagnino L, Testa A, Wichmann HE, Metspalu A, Meitinger T: Linkage disequilibrium patterns and tagSNP transferability among European populations. Am J Hum Genet 2005, 76(3):387-398.

37. O'Neill LA: Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 2005, 3(4):396-403.

38. Andreoukis E, Foxwell B, Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004, 202:250-265.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-5945/7/3/prepub